Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor Provides Final Update on the Phase III FORTRESS Study of Balixafortide in Patients with Advanced Her2 Negative Breast Cancer

08/03/2021 | 01:00pm EDT

Polyphor AG announced that its global Phase III FORTRESS study, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did also not meet its primary endpoint. As communicated, the analysis was conducted following the company's decision to initiate the closure of the FORTRESS study. The FORTRESS study investigates the efficacy and safety of the combination of balixafortide and eribulin versus eribulin monotherapy in patients with HER2 negative metastatic breast cancer with progressive disease after one to four lines of chemotherapy. Progression free survival (PFS) is the key primary endpoint of the study. 432 patients were included in the FORTRESS study, thereof 348 having had at least two lines of prior chemotherapy, a prespecified subgroup of the study. The study did not meet its primary endpoint of PFS in the overall population (n=432 patients): HR=1.10 (0.85, 1.41); p=0.445; median PFS: 3.5 m (B+E) vs. 4.0 m (E) and also not in the patients with at least 2 prior lines of chemotherapy according to the assessment of the blinded independent review committee (n=348 patients): HR=1.07 (0.81, 1.41); p=0.6158; median PFS: 3.5 m (B+E) vs. 4.0 m (E). Investigator assessment of PFS was consistent with the independent review committee analysis (HR=0.99 for the overall population and HR=1.05 for the > second line population). At the time of the PFS analysis, a pre-specified interim analysis of overall survival (OS) was conducted as well. There were no statistically significant differences for survival in the overall population (230 events): HR=1.08 (0.71,1.63); p=0.5897; median OS: 10.9 m (B+E) vs. 11.7 m (E) or in the > second line population (181 events): HR=1.08 (0.66, 1.77); p=0.6126; median OS: 11.0 m (B+E) vs. 11.2 m (E). The analysis of the safety and tolerance of balixafortide in combination with eribulin in the FORTRESS study was consistent with the previously reported safety profile with a numerically higher number of patients having had serious adverse events (28.4% B+E vs. 26.5% E) or adverse events of a grade 3 or higher severity (68.3% B+E vs. 63.7% E). Based on these results, the FORTRESS study will be closed and the pre-specified secondary efficacy analysis of OS after reaching 284 events in the overall population will not be performed.


© S&P Capital IQ 2021
All news about POLYPHOR AG
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/15La Commission des OPA constate l'absence d'obligation de présenter une offre publique d..
DJ
10/15Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer ..
DJ
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
More news
Financials
Sales 2021 1,00 M 1,09 M 1,09 M
Net income 2021 -41,4 M -45,1 M -45,1 M
Net Debt 2021 76,8 M 83,7 M 83,7 M
P/E ratio 2021 -0,47x
Yield 2021 -
Capitalization 21,4 M 23,3 M 23,3 M
EV / Sales 2021 98,3x
EV / Sales 2022 5,65x
Nbr of Employees 52
Free-Float 82,3%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,74 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Gökhan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-78.65%23
CSL LIMITED5.12%101 908
WUXI BIOLOGICS (CAYMAN) INC.13.52%63 685
SAMSUNG BIOLOGICS CO.,LTD.5.93%49 240
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.9.50%39 728